B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis

Jacob M van Laar

doi:10.1186/ar2977

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.

Original language	English
Pages (from-to)	112
Journal	Arthritis Research & Therapy
Volume	12
Issue number	2
DOIs	https://doi.org/10.1186/ar2977
Publication status	Published - 2010

Keywords

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
B-Lymphocytes
Clinical Trials as Topic
Humans
Immunologic Factors
Lymphocyte Depletion
Recovery of Function
Rituximab
Scleroderma, Diffuse
Skin
Treatment Outcome
Comment
Editorial

Access to Document

10.1186/ar2977

Cite this

@article{c4f55317a0b04b938d2a20355a6b076e,

title = "B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis",

abstract = "Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.",

keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, B-Lymphocytes, Clinical Trials as Topic, Humans, Immunologic Factors, Lymphocyte Depletion, Recovery of Function, Rituximab, Scleroderma, Diffuse, Skin, Treatment Outcome, Comment, Editorial",

author = "{van Laar}, {Jacob M}",

year = "2010",

doi = "10.1186/ar2977",

language = "English",

volume = "12",

pages = "112",

journal = "Arthritis Research & Therapy",

issn = "1478-6354",

publisher = "BioMed Central",

number = "2",

}

TY - JOUR

T1 - B-cell depletion with rituximab

T2 - a promising treatment for diffuse cutaneous systemic sclerosis

AU - van Laar, Jacob M

PY - 2010

Y1 - 2010

N2 - Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.

AB - Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B cells and on interleukin-6 and BAFF (B-cell activating factor of tumor necrosis factor family). The excellent safety profile of rituximab in this and other trials warrants further well-designed clinical trials in larger patient groups combined with comprehensive biomarker studies.

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Murine-Derived

KW - B-Lymphocytes

KW - Clinical Trials as Topic

KW - Humans

KW - Immunologic Factors

KW - Lymphocyte Depletion

KW - Recovery of Function

KW - Rituximab

KW - Scleroderma, Diffuse

KW - Skin

KW - Treatment Outcome

KW - Comment

KW - Editorial

U2 - 10.1186/ar2977

DO - 10.1186/ar2977

M3 - Article

C2 - 20441607

SN - 1478-6354

VL - 12

SP - 112

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 2

ER -

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this